HIVandHepatitis.com
 HIV and AIDS: Top News Articles  
HIV and AIDS: FDA-approved Treatments 
HIV and AIDS: Experimental Treatments
 Google Custom Search

Elvitegravir (GS-9137)
GS-9160 and GS-9350 and GS-9148

Investigational Pharmaco-enhancer GS-9350 Equals Ritonavir (Norvir) as a Booster for Atazanavir (Reyataz)
9/25/09

Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity
9/12/09

Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir
2/21/09

Viral Resistance to the HIV-1 Integrase Inhibitor GS-9160
2/10/09

GS-9350: A Pharmacoenhancer Without Anti-HIV Activity
2/10/09

High Resolution Crystallographic Analysis of the Competitive Binding of a Novel Nucleotide Analog GS-9148-Diphosphate to HIV-1 Reverse TranscriptaseEB
- 2/10/09

Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor Elvitegravir
- 1/20/09

Gilead Announces Start of Phase III Efficacy Trial of Experimental Integrase Inhibitor Elvitegravir in Treatment-experienced HIV Patients
7/25/08

Ritonavir-boosted Elvitegravir Has Potent and Durable Activity in Treatment-experienced Patients with Active Optimized Background Therapy
9/26/07

Lack of Clinically Relevant Drug Interactions Between Ritonavir-boosted Elvitegravir and Experimental NNRTI Etravirine (TMC125)
9/26/07

Experimental Integrase Inhibitor Elvitegravir Has Additive to Synergistic Interactions with Other Antiretrovirals in vitro and No Relevant PK Drug Interaction with Darunavir/ritonavir or Tipranavir/ritonavir
8/03/07

Integrase Inhibitor Elvitegravir from Gilead Sciences Demonstrates Potent and Durable Activity at 24-weeks in Treatment-experienced HIV Patients
3/06/07


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved Therapies for HIV and AIDS
Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir)
Viracept (nelfinavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry (maraviroc)
Fixed-dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)
Experimental Treatments